Healthcare Industry Veteran Jamie Condie Joins Selux Diagnostics' Board of Directors
February 14, 2023 07:30 ET
|
Selux Diagnostics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced today that...
FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing
January 19, 2023 07:00 ET
|
Selux Diagnostics
BOSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received...
Global Antibiotic Resistance Market Research Report 2023: The Changing Road to New Antibiotics & Technologies with 5 Year Forecasts
January 13, 2023 05:03 ET
|
Research and Markets
Dublin, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Global Antibiotic Resistance Market Report 2022: New Technologies and New Drugs are Under Development to Capture this Growing Market
April 14, 2022 04:08 ET
|
Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Global Antibiotic Resistance Markets Report 2021: Therapeutic Technology Development Opportunities by Pathogen and Therapy Type 2020-2024
August 31, 2021 05:53 ET
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. ...
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
May 18, 2021 07:00 ET
|
Summit Therapeutics Inc.
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against...
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
January 26, 2021 08:00 ET
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
October 26, 2020 09:00 ET
|
RedHill Biopharma Ltd.
H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance
September 09, 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...